Is MIR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Mirion Technologies (MIR) rests on Nuclear power tailwind: Renewed global interest in nuclear energy, including plant life extensions, new builds and small modular reactors, drives demand for Mirion's detection and safety instrumentation. Revenue (FY2025) is ~$925M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation, so much of the story depends on adjusted figures. Whether MIR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Mirion Technologies (NYSE: MIR) designs and sells radiation detection, measurement, analysis and monitoring products across two segments: Nuclear & Safety, which serves nuclear power plants, defense, research labs and industrial customers, and Medical, which supports cancer-care delivery, medical diagnostics and practitioner radiation safety. The company came public through a 2021 SPAC merger and describes itself as the only pure-play public company of its scale in radiation measurement, giving investors combined exposure to the nuclear energy revival and advanced medical applications. Much of its value sits in a large installed base of equipment, dosimetry services and recurring aftermarket revenue. The investment picture is a growth-and-backlog story running ahead of reported bottom-line profits. Revenue is expanding at a double-digit pace, helped by nuclear power demand and acquisitions such as Paragon and Certrec, and backlog has climbed past $1.1 billion. At the same time, Mirion carries meaningful debt, high interest costs and a history of GAAP net losses, so the case rests heavily on adjusted EBITDA, free cash flow conversion and continued order momentum rather than clean accounting earnings.
What's the case for buying MIR?
1. Nuclear power tailwind
Renewed global interest in nuclear energy, including plant life extensions, new builds and small modular reactors, drives demand for Mirion's detection and safety instrumentation. Management pointed to nuclear power demand as the main reason first-quarter 2026 orders (excluding acquisitions) rose about 19 percent. This positions the company as an infrastructure supplier to the energy-transition and grid-reliability theme.
2. Backlog and recurring revenue
Backlog expanded to roughly $1.1 billion, up 19 percent excluding M&A and 38 percent including acquisitions, giving forward visibility. A large installed base generates aftermarket parts, dosimetry services and software revenue that tends to be higher-margin and more recurring than one-time equipment sales.
3. Acquisitions and Medical segment
Mirion actively acquires niche players (for example Paragon and Certrec) to expand its nuclear-services footprint and add capabilities. Its Medical segment supplies quality-assurance and dosimetry tools for radiation oncology and diagnostics, adding a healthcare growth vector that is less tied to the nuclear capital cycle.
4. Margin and cash-flow expansion
The 2026 plan targets adjusted EBITDA of roughly $285 to $300 million and adjusted free cash flow of about $155 to $175 million, implying improving profitability and cash conversion. Better operating leverage on a growing installed base is central to closing the gap between adjusted metrics and GAAP results.
What are the risks to MIR?
Mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation, so much of the story depends on adjusted figures. The balance sheet carries meaningful debt (around $1.2 billion) and interest expense, which pressures net income and adds sensitivity to rates. Growth leans on acquisitions, creating integration, goodwill and execution risk. Nuclear project timing can be lumpy and dependent on government funding and utility capital budgets, and a large share of revenue ties to a niche end market. The shares have been volatile, down meaningfully year to date at points in 2026 even after strong quarterly orders.
How is MIR valued? (as of JULY 2026)
Snapshot for MIR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$925M
- Revenue (Q1 2026): ~$258M (+27.5% YoY)
- 2026 rev growth guidance: ~22% to 24%
- 2026 Adj. EBITDA guidance: ~$285M to $300M
- 2026 Adj. EPS guidance: ~$0.48 to $0.55
- Market cap: ~$4B
Mirion trades as a growth-oriented industrial where adjusted EBITDA and free cash flow, not GAAP EPS, anchor most valuation work given ongoing net losses and heavy interest costs. Backlog above $1.1 billion and double-digit order growth support the multiple, but roughly $1.2 billion of debt keeps leverage in focus. Reported figures vary by source and date, so confirm current numbers before relying on them.
How do you decide if MIR is a buy?
Rather than asking whether MIR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MIR indirectly through an index or sector ETF before adding more.
For the full picture, see the MIR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MIR against your real portfolio and see your actual exposure before deciding.
The bottom line on MIR
The bottom line: Mirion Technologies's story right now is Nuclear power tailwind, with revenue (fy2025) at ~$925M. If you believe that narrative continues, the call is about sizing MIR sensibly and checking overlap with what you own; if you doubt it (the risk: mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation, so much of the story depends on adjusted figures.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MIR with Walnut
Use Mirion Technologies as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MIR a good stock to buy right now?
+
The case for Mirion Technologies right now is Nuclear power tailwind, with revenue (fy2025) at ~$925M. If you believe that thesis holds, MIR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation, so much of the story depends on adjusted figures. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Mirion Technologies do?
+
Mirion Technologies (NYSE: MIR) designs and sells radiation detection, measurement, analysis and monitoring products across two segments: Nuclear & Safety, which serves nuclear pow
What are the main risks of MIR?
+
Mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation, so much of the story depends on adjusted figures. The balance sheet carries meaningful debt (around $1.2 billion) and interest expense, which pressures net income and adds sensitivity to rates. Growth leans on acquisitions, creating integration, goodwill and execution risk. Nuclear project timing can be lumpy and dependent on government funding and utility capital budgets, and a large share of revenue ties to a niche end market. The shares have been volatile, down meaningfully year to date at points in 2026 even after strong quarterly orders.
What does Mirion Technologies do?
+
Mirion makes radiation detection, measurement, analysis and monitoring equipment and services. It serves nuclear power plants, defense, research labs and industrial users through its Nuclear & Safety segment and cancer-care and diagnostics customers through its Medical segment.
What is the MIR stock ticker and where does it trade?
+
MIR is the New York Stock Exchange ticker for Mirion Technologies, Inc. The company became publicly traded in 2021 through a merger with a special purpose acquisition company (SPAC).
Is Mirion Technologies profitable?
+
Mirion generates positive operating income and adjusted EBITDA, but it has reported GAAP net losses driven by amortization and high interest expense. Investors often focus on adjusted EBITDA and free cash flow rather than reported net income.
How is Mirion tied to nuclear energy?
+
A large part of Mirion's revenue comes from equipment and services for nuclear power plants, including detection, dosimetry and safety systems. Growing interest in nuclear power, plant life extensions and small modular reactors is a key demand driver for the company.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MIR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.